

In Reply: We thank Dr. Modesto-Lowe and colleagues for their comments. We agree that primary care providers need to increase their efforts to diagnose patients with obesity and adiposity-related comor-bidities and to discuss with patients the therapeutic options including behavioral, pharmacotherapy,

and possibly bariatric surgery. Pharmacotherapy should not be considered a last resort as antiobesity agents are safe and effective and should be offered for patients with a body mass index of 30 kg/m² or greater and with a body mass index over 27 kg/m² in the presence of obesity-related comorbidity. Though we also recognize that the cost of antiobesity medications and the lack of insurance coverage for them continue to be major barriers to the regular use of these agents.

In general, primary care doctors need to become more comfortable discussing obesity as a medical problem that requires treatment like all other medical problems.

Yael Mauer, MD, MPH
Department of Internal Medicine and Geriatrics
Cleveland Clinic
Cleveland, OH

Marcie Parker, PharmD, BCACP
Ambulatory Care Clinical Specialist
Department of Pharmacy
Cleveland Clinic
Beachwood, OH

Sangeeta Kashyap MD
Professor of Medicine, Cleveland Clinic
Lerner College of Medicine of Case
Western Reserve University;
Associate Program Director, Endocrinology,
Diabetes, and Metabolism Fellowship
Cleveland Clinic
Cleveland, OH
Associate Editor, *Journal of Clinical
Endocrinology and Metabolism*

doi:10.3949/ccjm.88c.12004